Verismo Therapeutics
Megan Blair is an Associate Scientist at Verismo Therapeutics since August 2023, previously serving as a Postdoctoral Scientist at WuXi Advanced Therapies, where contributions included qualifying CAR T-cell therapies and developing new analytical methods in a GLP/GMP environment. As a Ph.D. Candidate at the University of Pennsylvania, Megan focused on branched-chain amino acid catabolism in skeletal muscle, producing significant research on type 2 diabetes and collaborating with Pfizer's Internal Medicine Research Unit. Early career experience includes roles as a Research Assistant at Boston Children's Hospital, where work involved optimizing transplant techniques and conducting drug screenings, as well as research positions at Hamilton College and MIT, focusing on obesity and cytokine research. Educational credentials comprise a Ph.D. in Cell and Molecular Biology and a B.A. in Biology.
Verismo Therapeutics
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options.